Search results
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga via Yahoo Finance· 14 hours agoOn Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) also reported durable efficiency of...
FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com
Investing.com· 7 days agoMerck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via AOL· 2 days agoMonday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of...
Moderna and MSD share encouraging three-year data from trial of melanoma therapy
Clinical Trials Arena via Yahoo Finance· 23 hours agoPharmaceutical companies Moderna and Merck & Co (MSD) have announced positive results from the Phase...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 2 days agoAs Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 7 days agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy
FierceBiotech· 7 days agoMerck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. Merck will take on a pipeline of vision ...
Merck to buy eye drug developer for $1.3B
BioPharma Dive via Yahoo Finance· 7 days agoAn acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Zacks via Yahoo Finance· 6 days agoMerck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a...
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Simply Wall St. via Yahoo Finance· 4 days agoWhen we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that Merck & Co.